The frequency of CDKN2A SCND detected by single nucleotide polymorphism (SNP) microarray, WGS or WES was found to range from 30% to 60% in bladder cancer, melanoma, head and neck cancer, pleural mesothelioma, glioblastoma, and esophageal squamous cell cancer (ESCC), with an average frequency of 13% in pan-cancer datasets in The Cancer Genome Atlas (TCGA) (Figure S1A) (2–6). Here, CDKN2A is linked to esophageal squamous cell carcinoma.